Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers Sells 31,780 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 31,780 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $82.33, for a total value of $2,616,447.40. Following the transaction, the chief financial officer now owns 189,320 shares of the company’s stock, valued at approximately $15,586,715.60. This trade represents a 14.37 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

James William Rogers also recently made the following trade(s):

• On Wednesday, February 5th, James William Rogers sold 8,712 shares of Tempus AI stock. The stock was sold at an average price of $67.57, for a total value of $588,669.84.
• On Monday, December 16th, James William Rogers sold 1,468 shares of Tempus AI stock. The stock was sold at an average price of $40.23, for a total transaction of $59,057.64.
• On Wednesday, December 11th, James William Rogers sold 83,025 shares of Tempus AI stock. The shares were sold at an average price of $42.30, for a total value of $3,511,957.50.

Tempus AI Price Performance

Shares of TEM stock opened at $76.72 on Friday. The firm’s fifty day moving average price is $49.75 and its two-hundred day moving average price is $51.44. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $91.45. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

Analyst Upgrades and Downgrades

TEM has been the subject of several analyst reports. Guggenheim assumed coverage on Tempus AI in a research report on Monday, December 9th. They set a “buy” rating and a $74.00 target price for the company. Bank of America lifted their price objective on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, December 13th. William Blair lowered shares of Tempus AI from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. Wolfe Research assumed coverage on shares of Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $56.00 price target on shares of Tempus AI in a research report on Tuesday, January 14th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $58.55.

Institutional Investors Weigh In On Tempus AI

Several hedge funds have recently bought and sold shares of the company. First Horizon Advisors Inc. acquired a new position in shares of Tempus AI during the 3rd quarter worth approximately $30,000. Operose Advisors LLC acquired a new position in shares of Tempus AI in the fourth quarter valued at $25,000. Farther Finance Advisors LLC acquired a new position in shares of Tempus AI in the fourth quarter valued at $34,000. Prestige Wealth Management Group LLC raised its position in shares of Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after purchasing an additional 965 shares during the period. Finally, NewEdge Advisors LLC acquired a new stake in shares of Tempus AI during the 4th quarter worth about $49,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.